Catinazzo Thomas sold $336K of RLAY
Catinazzo Thomas (Chief Financial Officer) sold 17,717 shares of Relay Therapeutics, Inc. (RLAY) at $18.94 ($0.34M total) on 2026-09-08 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CFO's sale is modest and likely has limited price impact, but it provides transparency for shareholders.
Market read
Primary insider sale disclosure with low materiality; relevant for short‑term monitoring of RLAY.
What to watch
Potential upcoming clinical data releases or partnership announcements could outweigh the insider sell.
Background
Form 4 filing discloses insider transactions required by the SEC; such filings are primary sources of corporate insider activity.
Ticker impact
CFO Catinazzo Thomas sold 17,717 shares of Relay Therapeutics for $335,560 via a 10b5‑1 plan, reducing his stake to 122,851 shares.
minor downward pressure or flat price action
Sale amount is under $1M and represents a small percentage of total holdings; market typically discounts small insider sells.
Market effects
Minimal impact on biotech sector; no broader industry signal.
No regional effect beyond the company's share price.
Limited global relevance; only relevant to investors in RLAY.
Counterpoint
The sale could be a routine portfolio rebalancing rather than a lack of confidence, so traders might ignore it.
Key entities
- companyRelay Therapeutics, Inc.
Biopharma developing precision medicines; ticker RLAY.
- personCatinazzo Thomas
Chief Financial Officer of Relay Therapeutics.